We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real‐life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study.
- Authors
Dragotto, Martina; Capalbo, Eugenio; Cartocci, Alessandra; Manzo Margiotta, Flavia; Michelucci, Alessandra; Rosi, Elia; Ricceri, Federica; Simoni, Barbara; Savarese, Imma; Milanesi, Nicola; Rossari, Susanna; Magnano, Michela; Romanelli, Marco; Rubegni, Pietro; Prignano, Francesca; Di Cesare, Antonella; Panduri, Salvatore; Pescitelli, Leonardo; Trovato, Emanuele
- Abstract
Although clinical trials[5] and real-world studies[[6], [8], [10]] have investigated its role in these patients, there are no comparative studies specifically evaluating the efficacy of Risankizumab according to body mass index (BMI). All these data lead us to postulate that Risankizumab represents an optimal molecule for the management of patients with moderate-to-severe psoriasis, regardless of BMI. Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study.
- Subjects
BODY mass index; ADALIMUMAB; INFORMED consent (Medical law); ADIPOSE tissue diseases; RETROSPECTIVE studies; WHITE adipose tissue
- Publication
Journal of the European Academy of Dermatology & Venereology, 2023, Vol 37, Issue 8, pe1075
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.19117